MedPath

Therapeutic Endpoint in Pediatric IBD Conditions

Recruiting
Conditions
Colitis, Ulcerative
Inflammatory Bowel Diseases
Crohn Disease
Interventions
Other: AlgometRx Nociometer
Registration Number
NCT06065228
Lead Sponsor
Children's National Research Institute
Brief Summary

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Male or female ≥ 6 years of age at screening.
  • Documentation of an IBD diagnosis as evidenced by history
Exclusion Criteria
  • Documented history of eye disease precluding pupillometry
  • Patients who are unwilling or unable to participate due to developmental delays or ongoing psychological diagnoses.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
UCAlgometRx Nociometer-
CDAlgometRx Nociometer-
Primary Outcome Measures
NameTimeMethod
The primary objective of this study is the measurement of the nociceptive index for clinical output.1 Year
Secondary Outcome Measures
NameTimeMethod
The secondary objective of this study is the characterization of the nociceptive index in IBD populations in response to standard of care interventions.1 Year

Trial Locations

Locations (1)

Children's National Health System

🇺🇸

Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath